Comparative Pharmacology
Head-to-head clinical analysis: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE versus MYTESI.
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, allowing for greater absorption of water and electrolytes. It also decreases fecal volume and increases stool consistency. Simethicone reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and passage via belching or flatulence.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
2 tablets (4 mg loperamide hydrochloride / 250 mg simethicone) orally after first loose stool, then 1 tablet (2 mg/125 mg) after each subsequent loose stool; maximum 4 tablets (8 mg/500 mg) per day for no more than 2 days.
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Loperamide: 7-14 hours (mean 10.8 hours) in healthy adults; prolonged to 18-26 hours in hepatic impairment.
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Loperamide: 97% fecal, 3% renal. Simethicone: excreted unchanged in feces.
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category A/B
Category C
Antidiarrheal
Antidiarrheal